Not available
Quote | Puma Biotechnology Inc (NASDAQ:PBYI)
Last: | $4.99 |
---|---|
Change Percent: | -0.19% |
Open: | $5.18 |
Close: | $4.99 |
High: | $5.29 |
Low: | $4.925 |
Volume: | 289,049 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
News | Puma Biotechnology Inc (NASDAQ:PBYI)
2024-03-20 10:06:37 ET More on Puma Biotechnology Puma Biotechnology, Inc. 2023 Q4 - Results - Earnings Call Presentation Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript Puma Biotechnology dips after dismissal of its suit was granted by a federal jud...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational New Drug Application (IND) submission has been reviewed, and Puma can proceed with the clinical development of alisertib fo...
Message Board Posts | Puma Biotechnology Inc (NASDAQ:PBYI)
Subject | By | Source | When |
---|---|---|---|
Awesome weekly chart | mitcheroo | investorshub | 01/26/2023 1:06:50 AM |
znewcar1: $PBYI 20% v1,3M c4.50 f45,6M H4.60 ML2.08 | znewcar1 | investorshangout | 11/22/2022 4:15:11 AM |
Oh man got caught up on the pump | Roadtojourney | investorshub | 01/12/2022 11:09:49 PM |
Historic short interest: | XenaLives | investorshub | 11/22/2021 2:12:16 PM |
Institutional Shares (Long) 36,969,527 - 90.42% (ex 13D/G) - | XenaLives | investorshub | 11/22/2021 2:10:05 PM |
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational New Drug Application (IND) submission has been reviewed, and Puma can proceed with the clinical development of alisertib fo...
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will attend TD Cowen’s 44 th Annual Health Care Conference, which will be held March 4 – 6, 2024, at the Bosto...